RenovoRx RNXT 深 沪
等待开盘 09-27 09:30:00 美东时间
1.18
+0.010
+0.85%
华盛通- 最 高1.2199
- 今 开1.17
- 成交量 21.60万股
- 最 低 1.17
- 昨 收 1.17
- 总市值 4324.22万
- 52周最高 1.6899
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.75
- 委 比 57.06%
- 总股本 3664.59万
- 历史最高 16.74
- 量 比 0.27
- 振 幅 4.26%
- 历史最低 0.5306
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RenovoRx Completes First Registry-Eligible Patient Procedure In PanTheR Post-Marketing Registry Study At University Of Vermont Cancer Center
First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer CenterBaptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of Vermont Cancer Center
09-25 20:32
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
The first registry-eligible patient procedure in RenovoRx's PanTheR Post-Marketing Registry Study was completed at the University of Vermont Cancer Center. Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center have joined the study. The PanTheR registry aims to gather real-world safety and performance data of the FDA-cleared RenovoCath device for solid tumor patients. RenovoRx plans to expand patient enrollment and tre...
09-25 12:30
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
RenovoRx CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16-17, discussing the company's commercialization of RenovoCath and its Phase III TIGeR-PaC clinical trial for pancreatic cancer treatment. Bagai will highlight the trial's progress and the Data Monitoring Committee's recommendation to continue the study following the second interim analysis. The presentation will also cover ...
09-11 12:30
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
09-08 17:59
SRx Health Solutions Signed a Letter of Intent to Acquire the Assets of Royal Uranium
SRx Health Solutions, Inc. has signed a non-binding Letter of Intent to acquire 100% of Royal Uranium Inc.'s assets, expanding its mission to combine hard-asset energy royalties amid surging AI and data center power demand. The deal, subject to customary closing conditions, includes 18 uranium royalties across key jurisdictions. The acquisition aims to capitalize on global clean energy transition and growing demand for nuclear energy, with strate...
08-18 11:00
RenovoRx Announces The Independent Data Monitoring Committee For Its Ongoing Phase III TIGeR-PaC Trial Has Recommended To Continue The Study
"At the same time, we are very excited to report that the independent Data Monitoring Committee (DMC) for our ongoing Phase III TIGeR-PaC trial recently completed their review of our second pre-planned interim analysis
08-15 04:18
RenovoRx Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $422.00K Beat $329.67K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 8.05 percent. This is a 20 percent increase over losses of $(0.10) per share from the same
08-15 04:12
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
RenovoRx Expands RenovoCath Commercial Reach To 13 Cancer Centers
RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCathFour active cancer center customers are currently purchasing and
08-06 20:38
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
<p>RenovoRx expands its commercial presence with 13 cancer centers approved to purchase RenovoCath, including 4 repeat customers. The company hires Philip Stocton as Senior Director of Sales, leveraging his 25+ years in MedTech and interventional oncology. This growth underscores the demand for localized tumor treatments beyond traditional IV chemotherapy. RenovoCath's adoption highlights its potential to improve patient outcomes by reducing syst...
08-06 12:30
